
Opinion|Videos|January 20, 2025
Overview of Teplizumab for Delaying Onset and Progression of Type 1 Diabetes
Panelists discuss how teplizumab, the first FDA-approved disease-modifying therapy for Type 1 diabetes, can delay disease onset by targeting CD3+ T cells and preserving beta cell function in high-risk individuals.
Advertisement
Episodes in this series

Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Patient Care Online
1
First Oral Film Treatment for Erectile Dysfunction in Men Gains FDA Approval
2
Long-Term Data Support Sustained Bimekizumab Response in Hidradenitis Suppurativa
3
Weekly Dose Podcast: New Obesity Data, Insulin Guidance, and Mental Health Screening
4
Topline Phase 2 Data Show Roflumilast Cream Improves Atopic Dermatitis in Infants as Young as 3 Months
5


































































































































